DEMENTIA, how do we slow it down, earlier, safely and at population scale?. Japan scenario.

 KESUM (Biokesum®) as a first-choice. 

DEMENTIA & KESUM

 

1. Japan Scenario: Why Dementia Prevention Must Start Before Decline.

Japan is no longer asking “How do we treat dementia?”

The national question has shifted to:

·       “How do we slow it down, earlier, safely, and at population scale?”

As a super-aged society (≈30% aged ≥65), Japan faces:

·       ~7 million dementia patients by 2025

 

Estimated ¥14 trillion (~USD 90 billion) annual burden by 2030

·       Shrinking healthcare workforce

·       Rising demand for community-based, preventive, non-pharmaceutical interventions

 

Japan’s post-2025 direction emphasizes:

·       Risk reduction

·       Early intervention

·        Community-integrated care

·       Safe, long-term solutions suitable for daily use

This creates a critical gap:

·       There are very few natural, clinically proven interventions that can objectively show support for brain health before dementia becomes irreversible.

 

2. Where KESUM (Biokesum®) Fits Perfectly

The Key Scientific Insight

Dementia progression is strongly linked to:

·       Declining neurogenesis

·       Reduced BDNF (Brain-Derived Neurotrophic Factor)

 

·       Metabolic risk factors (e.g. high triglycerides, cholesterol)

Most supplements claim brain benefits.

KESUM demonstrates measurable change.

Clinical Signals from Biokesum® (6-Month Intervention)

BDNF: +2.03% increase

Triglycerides: −19.05% reduction

 

Placebo group showed BDNF decline (−19.19%) and TG increase (+10.17%)

(Two-way mixed ANOVA, p < 0.05)

 

 

This is not symptomatic relief.

This is biological support of brain resilience.                                                                                                                                       

 

In a Japanese policy context, this aligns directly with:

·       Risk factor modification

·       Neuroprotection

·       Slowing not “curing” dementia progression

·       Safe, daily, long-term use in elderly populations

 

3. Why “2% BDNF Increase” Matters (Especially for Japan)

In neurodegenerative disease:

·       Decline is the norm

·       Even stabilization is clinically meaningful

·       A positive increase is rare

 

 

A 2% increase in BDNF over 6 months may appear modest,

but against an expected age-related decline, it represents:

·       Slowed neuronal loss

·       Improved synaptic plasticity

·       Better cognitive reserve

 

This is exactly the type of outcome Japan’s dementia policy prioritizes:

·       “Delay progression, preserve dignity, extend independent living.”

 

4. Comparison Table: KESUM vs Common “Brain Supplements”

Ingredient	Evidence for BDNF Increase	Reported % Change	Clinical Human Data	Key Limitation
KESUM (Biokesum®)	✅Yes	+2.03%	✅Human clinical trial	Needs wider international awareness
Ginkgo biloba	⚠️Inderct	❌ Not quantified	⚠️Mixed results	No confirmed BDNF %
Green Tea (EGCG).	⚠️Preclinical	❌ Not quantified	⚠️Limited	Mostly animal / in vitro
Curcumin	⚠️Suggested	❌ Not quantified	⚠️Bioavailability issues	Low absorption
Fish Oil ( Omega 3 )	⚠️Supportive	❌ Not quantified	✅Cognitive support	No direct BDNF %
Mushroom extracts ( Lions Mane, etc.)	⚠️Preclinical	❌ Not quantified	⚠️Limited	Early-stage evidence
Garlic	❌Weak	❌Not available	❌Minimal	Not brain-specific
Bacopa monnieri	⚠️Cognitive claims	❌ Not quantified	⚠️Variable	No BDNF % data

 

KESUM.

https://shop.biotropicsmalaysia.com/biotropics-en 

Key Differentiator:

KESUM is the only natural extract among these with a quantified human BDNF increase.

 

5. Japan: “Do It Right First”

 

Japan’s Unspoken Reality

Once dementia is clinically obvious:

·       Neuronal damage is already advanced

·       Drug efficacy is limited

·       Costs escalate rapidly

 

The KESUM Narrative

“Don’t wait for dementia. Strengthen the brain earlier.”

 

KESUM supports Japan’s strategy by:

·       Acting before diagnosis

·       Supporting neurogenesis & metabolic health

·       Being suitable for community-level adoption

·       Aligning with person-centered, dignity-preserving care

 

Positioning Statement (Japan-Ready)

KESUM is not a dementia drug. It is a brain-resilience solution for an aging society.

 

6. Strategic Fit with Japan’s Post-2025 Dementia Direction

Japan Policy Priority	How KESUM Aligns
Risk reduction	Lower triglycerides, supports brain metabolism
Early intervention	Suitable for pre-dementia & MCI populations
Non-pharmaceutical	Natural, safe, long- term use
Community care	Easy integration into daily routines
Cost control	Prevention-oriented vs late-stage treatment

 

 

 

 

7. Final Takeaway for Japanese Stakeholders.

If Japan’s goal is to slow dementia, not chase a cure, then KESUM deserves serious consideration.

 

It represents:

✔ Evidence, not claims

✔ Prevention, not reaction

✔ Measurable biology, not marketing

 

For a 65+ population, “doing it right first” matters. KESUM fits that philosophy, scientifically and culturally.